Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2014

View Archived Issues

Takeda Pharmaceuticals charts milestones of second quarter of fiscal 2014

Daiichi Sankyo presents highlights of second quarter of fiscal 2014

Fujifilm to invest in PET radiopharmaceuticals

Xoma opens enrollment in phase III study of gevokizumab for pyoderma gangrenosum

AstraZeneca and Pharmacyclics collaborate on combination trials of ibrutinib in oncology

Cabozantinib extends progression-free survival in phase II trial in NSCLC

Astellas and Proteostasis Therapeutics form collaboration targeting the unfolded protein response

LEO Pharma licenses Japan Tobacco's JTE-052 for dermatology applications

Research uncovers novel gene mutations underlying familial hypertrophic cardiomyopathy

BioLineRx reports final results of phase I/II study for BL-7010

Alion and Medical Prognosis Institute to identify response biomarkers for ion channel inhibitor

Novel cystine derivatives inhibit stone formation in vivo

Aegerion Pharmaceuticals to acquire Myalept from AstraZeneca

New pan-RAF inhibitors effective in melanomas resistant to BRAF or BRAF/MEK inhibitors

Effectiveness of a bumped kinase inhibitor against toxoplasmosis

Novel ACC2 inhibitors disclosed by Boehringer Ingelheim

Incyte divulges novel FGFR-1, -2 and -3 inhibitors

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Astellas Pharma discloses new D1 receptor PAMs

Actelion researchers present novel antibacterial compounds

Investigators at CSIR report new anticancer rohitukine analogues

Beloranib as promising treatment of obesity and food-related behavior in Prader-Willi Syndrome

Spark Therapeutics' SPK-RPE65 receives FDA breakthrough therapy designation

Gilead files NDA for elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV

FDA advisory committee recommends approval of Triferic

FDA issues complete response letter to AEterna Zentaris for Macrilen NDA

F-star spins off assets into F-star Beta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...